EGFR and cancer: Activation of the ERBB growth factor signaling pathway was identified in post-treatment resistant cancer cells in the majority of patient tumors across treatment arms (73% of patients (30/41) showed significant activation in post-treatment versus pre-treatment paired cancer samples).